Richard Aldrich
CIK 1185039 · last filed 2023-03-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
PTCT price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
WALTHAM, MA 02451
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Director | 0 | $8.37 | $0 | -$1.19M | 20 | 2023-03-06 |
| Tempest Therapeutics, Inc. (MLND) Delisted | Director | 4,687 | $15.90 | $74.5K | $0 | 1 | 2018-12-11 |
| KalVista Pharmaceuticals, Inc. (KALV) Delisted | Director | 934,484 | $27.00 | $25.23M | $4.87M | 5 | 2018-10-05 |
| Tempest Therapeutics, Inc. (OVAS) Delisted | Director | 69,552 | — | — | $8.55M | 37 | 2018-10-02 |
| PTCT | Director | 1,050,104 | $64.31 | $67.53M | $11.11M | 5 | 2015-06-10 |
| VSTM | Director | 273,081 | $8.96 | $2.45M | $270.2K | 23 | 2013-11-12 |
| BIOSPECIFICS TECHNOLOGIES CORP (BSTC) Delisted | 10%+ Owner | 671,351 | — | — | $1.34M | 4 | 2008-11-14 |
| SEQUENOM INC (SQNM) Delisted | 10%+ Owner | 5,872,966 | — | — | $0 | 1 | 2008-07-14 |
| CRIS | 10%+ Owner | 3,125 | $0.63 | $2.0K | -$1.82M | 1 | 2008-04-17 |
| ARADIGM CORP (ARDM) Delisted | 10%+ Owner | 189,210 | — | — | $259.8K | 1 | 2008-01-16 |
| Sirtris Pharmaceuticals, Inc. (SIRT) Delisted | Director | 38,095 | — | — | $0 | 1 | 2007-05-31 |
| LIPID SCIENCES INC/ (LIPD) Delisted | 10%+ Owner | 3,713,962 | — | — | $420 | 1 | 2007-03-28 |
Recent Filings · Page 3 of 11
101 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-10-19 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Buy (P) | +565,065 | $4.87M | EDGAR |
| 2017-10-03 | Tempest Therapeutics, Inc. (OVAS) Delisted | Grant (A) | +7,482 | $0 | EDGAR |
| 2017-09-29 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-07-05 | Tempest Therapeutics, Inc. (OVAS) Delisted | Grant (A) | +6,810 | $0 | EDGAR |
| 2017-06-23 | Tempest Therapeutics, Inc. (OVAS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-06-19 | CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-04-04 | Tempest Therapeutics, Inc. (OVAS) Delisted | Grant (A) | +5,681 | $0 | EDGAR |
| 2017-03-27 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-01-04 | Tempest Therapeutics, Inc. (OVAS) Delisted | Mixed | +6,944 | $10.6K | EDGAR |
| 2016-11-29 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Grant (A) | +369,419 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.